- 4basebio PLC will supply clinical-grade opDNA® starting material for a multinational pharmaceutical innovator’s cell therapy program.
- The synthetic DNA will support an upcoming Phase I clinical trial, with TriLink BioTechnologies selected as the CDMO to manufacture the mRNA drug substance.
4basebio PLC will supply clinical-grade opDNA® starting material for a multinational pharmaceutical innovator’s latest cell therapy program. Financial terms of the agreement were not disclosed.
Under the agreement, 4basebio will provide synthetic DNA as a critical material for the client’s upcoming Phase I clinical trial. TriLink BioTechnologies, part of Maravai LifeSciences, has been selected as the contract development and manufacturing organization (CDMO) for the program and will manufacture the mRNA drug substance using its CleanCap® co-transcriptional capping technology.
The collaboration is intended to use 4basebio’s opDNA® as a starting material within established manufacturing workflows. The company said the program reflects its focus on providing an alternative to plasmid DNA for the development of genetic medicines.
“We’re excited to continue our relationship with this leading pharmaceutical innovator as they advance new molecules into the clinic. Working with TriLink enables 4basebio to integrate its starting material into established manufacturing workflows.”
Christine Wolosin, Chief Commercial Officer at 4basebio
Chad Decker, Senior Vice President, Global Sales at TriLink, said TriLink is the CDMO for the cell therapy program. He said the combination of its CleanCap® technology and 4basebio’s opDNA® starting material will support consistency from DNA template through finished drug substance.
